– USA, TX – Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced the appointment of Dr. Steve Ryder (M.D.) to its Board of Directors, effective July 11, 2022.
“We are thrilled to welcome Dr. Ryder to Reata’s board. He is joining us at a critical point in Reata’s development with our New Drug Application under review with the U.S. Food and Drug Administration for omaveloxolone for the treatment of patients with Friedreich’s ataxia. His knowledge will be invaluable to help us achieve our mission in developing innovative therapies that change patients’ lives for the better,” said CEO, Warren Huff.
About Dr. Steven W. Ryder
Dr. Steve Ryder brings over 35 years of experience in the biopharmaceutical industry, serving in various development roles globally. Most recently, Dr. Ryder has served as CMO of Rallybio Corporation since January 2019. From July 2013 through December 2018, Dr. Ryder served as CDO at Alexion Pharmaceuticals, Inc. Before that, Dr. Ryder served as President of Astellas Pharma Global Development, Inc. Dr. Ryder worked at Pfizer Inc. for 21 years where he held positions of increasing responsibility, including head of worldwide clinical development. He is the past-President of the American Society of Clinical Pharmacology and Therapeutics and has held leadership positions in the Health Section Governing Board, Regulatory Executive Committee, and Board of BIO, and the Science and Regulatory section of the Pharmaceutical Research and Manufacturers of America is a member of the Clinical Pharmacology Advisory Board of the PhRMA Foundation and is an active member of several editorial boards. Dr. Ryder has served as the industry representative on the U.S. Food and Drug Administration’s Metabolic/Endocrine Drugs Advisory Committee.
“I am excited to be joining Reata’s Board of Directors at this crucial time,” said Dr. Ryder. “I look forward to working with the other board members, as well as Reata’s management team, to prepare for the next stage in the Company’s growth and the potential commercial launch of omaveloxolone in the United States, subject to regulatory review and approval.”
Dr. Ryder earned an M.D. from the Icahn School of Medicine at Mount Sinai.
About Reata
Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates, omaveloxolone and bardoxolone, target the important transcription factor Nrf2 that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. Omaveloxolone and bardoxolone are investigational drugs, and their safety and efficacy have not been established by any agency.
For more information: https://reatapharma.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
